

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/00, A01N 43/04, C07H 21/04	A1	(11) International Publication Number: WO 98/02150 (43) International Publication Date: 22 January 1998 (22.01.98)
(21) International Application Number: PCT/US97/06103 (22) International Filing Date: 4 April 1997 (04.04.97) (30) Priority Data: 08/682,277 17 July 1996 (17.07.96) US (71) Applicant: MEDTRONIC, INC. [US/US]; 7000 Central Avenue N.E., Monneapolis, MN 55432 (US). (72) Inventors: STOKES, Kenneth, B.; 17581 Eidelweiss Street N.W., Anoka, MN 55304 (US). MORISSETTE, Josée; Apartment 306, 1101 Paul Parkway, Blaine, MN 55434 (US). (74) Agents: PRESTON, Albert, W., Jr. et al.; Woodcock, Washburn, Kurtz, Mackiewicz & Norris LLP, 46th floor, One Liberty Place, Philadelphia, PA 19103 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: SYSTEM FOR GENETICALLY TREATING CARDIAC CONDUCTION DISTURBANCES		
(57) Abstract <p>The present invention provides delivery systems for delivering conduction protein genetic material to cardiac cells in localized areas of the heart to improve the conductance therein. More specifically, there is provided a system for delivering connexin proteins or nucleic acid molecules encoding connexin proteins to a site in the heart which has been determined by mapping procedures to have a conduction disturbance. For cases where conduction is impaired, selected genetic material is delivered by Applicants' delivery system to cells around the disturbance area, in order to enhance overall conductivity patterns; in other cases, genetic material is selected to slow conduction in affected areas, so as to prevent, e.g., brady-tachy syndrome.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

SYSTEM FOR GENETICALLY TREATING CARDIAC CONDUCTION DISTURBANCES

FIELD OF THE INVENTION

The present invention relates to systems for
5 delivering conduction protein genetic material to cardiac
cells in localized areas of the heart to improve the
conductance therein.

BACKGROUND OF THE INVENTION

The conduction system of the human heart is
10 normally automatic, resulting in the contraction of the
atria and ventricles by means of electrical impulses that
originate in cardiac tissue. The cardiac cycle is separated
into the contraction phase (systole) and relaxation phase
(diastole). Although the rhythm of the cardiac cycle is
15 intrinsic, the rate of this rhythm is modified by autonomic
nerves and hormones such as epinephrine. The autonomic
nervous system is comprised of parasympathetic and
sympathetic nerves which release neurotransmitters such as
acetylcholine and norepinephrine, respectively.

20 The natural pacemaker of the human heart is
located in the posterior wall of the right atrium in a small
area, approximately 2 by 5 by 15 mm, referred to as the
sinoatrial node (SA node). The SA node initiates the
cardiac cycle of systole and diastole phases by generating
25 an electrical impulse that spreads over the right and left
atria, causing them to contract almost simultaneously. This
electrical impulse, referred to as the pacemaker potential,

is created by the depolarization of the myocardial cells of the SA node, which results from changes in membrane permeability to cations. When the cell membrane is depolarized to about -30 mV, an action potential is produced. This impulse then passes to the atrioventricular node (AV node), which is located on the inferior portion of the interatrial septum. The impulse then continues through the atrioventricular bundle, referred to as the bundle of His, which is located at the top of the interventricular septum. The bundle of His divides into right and left branches which lead to the right and left ventricles respectively. Continuous with both branches of the bundle of His are the Purkinje fibers, which terminate within the ventricular walls. Stimulation of these fibers causes the ventricles to contract almost simultaneously and discharge blood into the pulmonary and systemic circulatory systems.

Abnormal patterns of electrical conduction in the heart can produce abnormalities of the cardiac cycle and seriously compromise the function of the heart, sometimes being fatal. For example, patients having such cardiac conduction disturbances may suffer from sick sinus syndrome (SSS), "brady-tachy syndrome," bradycardia, tachycardia, and heart block. Artificial pacemakers are often used in patients which suffer from these cardiac conduction disturbances.

In SSS, the conduction problem relates to, inter alia, intermittent reentry of the electrical impulse within the nodal tissue, sometimes resulting in rapid heart beats. A dual chamber pacemaker is often used to sense atrial activity and control the ventricle at the appropriate rate.

In some congenital diseases such as "brady-tachy syndrome," bradycardia, a slow rate of impulse, and tachycardia, a rapid rate of impulse, occur intermittently. The disease can be fatal where long pauses allow premature ventricular contractions (PVCs) to occur in multiples, initiating tachycardia. A pacemaker and/or cardioverter can be used to control episodes of tachycardia, and conventional

- 3 -

demand type pacemakers have long been effective in treating bradycardia.

Excessive delay or failure of impulse transmission in abnormally slow impulse conduction is known as heart
5 block. Heart block is often caused by scar tissue disrupting the conduction system. The cardiac impulse is believed to normally spread from the SA node along internodal pathways to the AV node and ventricles within
10 0.20 seconds. Heart block occurs in three progressively more serious stages. In first-degree heart block, although all impulses are conducted through the AV junction, conduction time to the ventricles is abnormally prolonged. In second-degree heart block, some impulses are conducted to the ventricles, whereas some are not. In third-degree heart
15 block, no impulses from the natural pacemaker are conducted to the ventricles. This results in a slower ventricular contraction rate. The rate of contraction in this case is usually determined by the rate of the fastest depolarizing His-Purkinje cell distal from the block site. Typically,
20 heart rates in third-degree block are in the 20 to 60 bpm range, but can also be as low as zero in some cases.

Arrhythmias resulting from cardiac conduction disturbances can be treated with a variety of drugs that inhibit specific aspects of the cardiac action potentials
25 and inhibit the production or conduction of impulses along abnormal pathways. Drugs used to treat these arrhythmias block the fast Na⁺ channels (quinidine, procainamide, lidocaine), block the slow Ca⁺⁺ channel (verapamil), or block
β-adrenergic receptors (propranolol).

30 The cardiac conduction system, or electrical activation of the heart, involves the transfer of current, in the form of chemical ion gradients, from one myocardial cell to another. Conductive proteins in cardiac cells facilitate this transfer of current. Individual cardiac
35 cells express a plurality of gap junction channel proteins, through which ions traverse. The intercellular channels of gap junctions are assembled from individual membrane-

- 4 -

spanning connexin proteins, several of which have been cloned and sequenced in mammals. These proteins facilitate the transfer of ions from cell to cell and are responsible for electronic coupling of cells. Saffitz, et al., *J. Card. Electrophys.*, 1995, 6, 498-510.

5 Connexin proteins comprise a family of related proteins and include, for example, Cx43 (Fishman, et al., *J. Cell Biol.*, 1990, 111, 589-598), and Cx40 and Cx45 (Kanter, et al., *J. Mol. Cell Cardiol.*, 1994, 26, 861-868). Cx43
10 appears to be the most abundant connexin in the heart, with expression in the ventricle and atrial myocardium, and distal bundle of His and Purkinje fibers, while being absent from the SA node, AV node, and proximal bundle of His. Gourdie, et al., *J. Cell Sci.*, 1993, 105, 985-991, and
15 Davis, et al., *J. Am. Coll. Cardiol.*, 1994, 24, 1124-1132. Cx40 is most abundantly expressed in the atrial myocardium, and in the distal bundle of His and Purkinje fibers, while present at reduced levels in the ventricular myocardium, and the nodes. Gourdie, et al., *J. Cell Sci.*, 1993, 105, 985-
20 991, and Davis, et al., *J. Am. Coll. Cardiol.*, 1994, 24, 1124-1132. Cx45 is moderately expressed in the ventricle and atrial myocardium, and distal bundle of His and Purkinje fibers, while present at lower levels in the SA node, AV node, and proximal bundle of His. Gourdie, et al., *J. Cell*
25 *Sci.*, 1993, 105, 985-991, and Davis, et al., *J. Am. Coll. Cardiol.*, 1994, 24, 1124-1132. Cx43 and Cx40 connexins are relatively fast conductive proteins, whereas Cx45 is a relatively slow conductive protein.

Gene therapy has recently emerged as a powerful
30 approach to treating a variety of mammalian diseases. Direct transfer of genetic material into myocardial tissue in vivo has recently been demonstrated to be an effective method of expressing a desired protein. For example, direct myocardial transfection of plasmid DNA by direct injection
35 into the heart of rabbits and pigs (Gal, et al., *Lab. Invest.*, 1993, 68, 18-25), as well as of rats (Ascadi, et al., *The New Biol.*, 1991, 3, 71-81), has been shown to

- 5 -

result in expression of particular reporter gene products. In addition, direct *in vivo* gene transfer into myocardial cells has also been accomplished by directly injecting adenoviral vectors into the myocardium. French, et al.,
5 *Circulation*, 1994, 90, 2415-2424, and PCT Publication WO 94/11506.

It has long been desired to effectively treat conduction pathway abnormalities. To this end, conventional procedures including drug therapy, pacemaker technology, or
10 a combination thereof, have been employed. In contrast to these therapeutic procedures, Applicants' invention is directed to delivery systems for treating and/or correcting disturbances in the cardiac conduction pathway by delivering conduction protein genetic material into myocardial tissue.
15 In patients with cardiac conduction disturbances, it is desirable to locate the problematic area within the heart, and either treat the problematic cells to restore proper cardiac conduction or enhance the cardiac conduction of normal cells surrounding the problematic area. For example,
20 in a patient with heart block, a tract of normal, healthy cells surrounding the scar in the ventricle, which is causing the heart block, is identified and treated with Applicants' delivery system by expressing cardiac conduction proteins, such as, for example, gap junction proteins to
25 impart a faster or otherwise enhanced conduction system. In this case, the block can be effectively bridged, or shunted, resulting in a QRS of a width intermediate between a normally conducted beat and a PVC.

SUMMARY OF THE INVENTION

30 In accordance with the above, the primary purpose of Applicants' claimed invention is to provide delivery systems for treating cardiac conduction disturbances. Upon identifying a problematic area within the heart, conduction protein genetic material is selected such that expression of
35 a selected conduction protein corrects or improves the cardiac conduction of the cells in the problematic area.

- 6 -

Alternatively, expression of a selected conduction protein can improve the cardiac conduction of normal, healthy cells surrounding the problematic cells. Improvement of cardiac conduction can be manifested by a replacement, a speeding up, or a slowing down of the existing conduction pathway. The conduction protein genetic material comprises recombinant nucleic acid molecules comprising a nucleic acid molecule encoding the conduction protein inserted into a delivery vehicle, such as, for example, plasmids or adenoviral vectors, and the appropriate regulatory elements. Alternatively, the conduction protein genetic material comprises the conduction protein itself. Expression of the desired conduction protein from recombinant nucleic acid molecules is controlled by promoters, preferably cardiac tissue-specific promoter-enhancers, operably linked to the nucleic acid molecule encoding the conduction protein. The conduction protein is preferably a gap junction protein, such as, for example, the connexins Cx40, Cx43, and Cx45, which is used to correct or improve the cardiac conduction of cells within the problematic area. For example, if the cardiac conduction pathway disturbance is a heart block or bradycardia, Cx43 or Cx40 is preferably used. However, if the cardiac conduction pathway disturbance is tachycardia, Cx45 is preferably used. The cardiac conduction genetic material is delivered to specific sites within the heart by perfusion or injection of a therapeutically effective amount, which is that amount which corrects or improves the cardiac conduction of the myocardial cells. The therapeutically effective amount can be delivered to the specific site in the heart in a single dose or multiple doses, as desired.

The present invention provides a delivery system for delivering a therapeutically effective amount of a predetermined conduction protein genetic material to an identified cardiac location, the genetic material being selected for altering the conductivity of cardiac cells to which it is delivered. The delivery system includes the

- 7 -

selected genetic material contained in a reservoir, and a catheter subsystem for delivering the genetic material from the reservoir to the identified cardiac location so as to contact a plurality of cells in the proximity of the
5 selected cardiac location.

The delivery system may utilize an external reservoir for providing the genetic material, or alternately may utilize an implantable reservoir. In either embodiment, a controllable pump mechanism is provided for transferring
10 therapeutic doses of the genetic material from the reservoir, through a catheter, and to the selected cardiac location. The catheter subsystem may be of a type for direct introduction into the myocardium, as with a transthoracic procedure, or, more preferably, a endocardial
15 catheter having a distal tip portion adapted for positioning and injecting the genetic material into the myocardium from within a heart chamber. In a preferred embodiment, the catheter distal tip has a normally withdrawn helical needle, which is extendable when positioned in the vicinity of the
20 selected site so as to be screwed into the heart. The needle is hollow and connects with the catheter lumen so as to receive the pumped genetic material; it has one or more ports located so as to effectively release the genetic material for transduction into the mapped area. In another
25 preferred embodiment of the invention, the delivery system is combined with the mapping catheter such that once the selected site is identified, the delivery system, which is within the mapping catheter, is engaged without removing the mapping catheter. The delivery system can be used for one
30 treatment and then removed, or can be implanted for subsequent treatments, in which latter case it is controllable by an external programmer type device.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a flow diagram presenting the primary
35 steps involved in the practice of this invention, including mapping the patient's conductive system to determine the

- 8 -

location of the problem, choosing an appropriate genetic material, and expressing the genetic material in an appropriate dose into the determined location.

Figure 2 is a schematic representation of a delivery system in accordance with this invention, illustrating delivery of genetic material into a patient's heart at the chosen location.

Figure 3 is a schematic drawing of the distal portion of a catheter, which can be extendable and retractable, used for injecting a solution carrying chosen genetic material into a patient's heart.

Figure 4 illustrates the distal end of a catheter, having a distal portion which encloses an osmotic pump.

Figure 5 illustrates a delivery system in which the delivery means comprises a mapping catheter combined with a delivery system for injecting a solution carrying chosen genetic material into a patient's heart.

Figure 6A is a schematic representation of a delivery system in accordance with this invention, having a combined catheter and pacing lead, with a separate pump; Figure 6B is another embodiment of a combined pacing lead and delivery catheter having a reservoir located at the distal end of the catheter.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

Applicants' invention provides delivery systems for treating cardiac conduction pathway disturbances. A problematic area exhibiting, for example, SSS, "brady-tachy syndrome," bradycardia, tachycardia, or heart block, within the heart is identified by routine and conventional techniques known to the skilled artisan. Once the specific problem has been identified, conduction protein genetic material is selected such that expression of a selected conduction protein corrects or improves the cardiac conduction of the problematic cells or improves the cardiac conduction of normal cells surrounding the problematic cells. The conduction protein genetic material comprises

- 9 -

either the conduction protein itself or recombinant nucleic acid molecules comprising a nucleic acid molecule encoding the conduction protein inserted into a delivery vehicle, such as, for example, plasmid, cosmid, YAC vector, viral
5 vectors, and the like, and the appropriate regulatory elements. In preferred embodiments of the present invention, the nucleic acid molecule encoding the conduction protein is the full length coding sequence cDNA of a conduction protein, and is inserted into a plasmid or
10 adenoviral vector, such as, for example, pGEM3 or pBR322, and Ad5, respectively. The regulatory elements are capable of directing expression in mammalian cells, specifically human cells. The regulatory elements include a promoter and a polyadenylation signal. Expression of the desired
15 conduction protein is preferably controlled by cardiac tissue-specific promoter-enhancers, operably linked to the nucleic acid molecule encoding the conduction protein. The conduction protein is preferably a gap junction protein, such as, for example, the connexins Cx40, Cx43, and Cx45,
20 which is used to correct or improve the cardiac conduction of cells within the problematic area. The specific gap junction protein chosen is dependent upon the nature of the identified problem. For example, where the conduction is slow or non-existent, such as in heart block or bradycardia,
25 introduction of Cx40 or Cx43 would enhance conduction. In contrast, introduction of the slower conducting Cx45 into the AV node and His tissues would result in the prevention of brady-tachy syndrome and tachycardia. The conduction protein genetic material is preferably delivered in a
30 pharmaceutical composition comprising, for example, the conduction protein genetic material in a volume of phosphate-buffered saline with 5% sucrose. The cardiac conduction genetic material is delivered to specific sites within the heart by perfusion or injection of a
35 therapeutically effective amount, which is that amount which corrects or improves the cardiac conduction of the myocardial cells. The therapeutically effective amount can

be delivered to the specific site in the heart in single or multiple doses, as desired, using the delivery systems of the invention.

The present invention comprises a delivery system for delivering a therapeutically effective amount of conduction protein genetic material to a mapped cardiac location in such a way as to enhance the effective conduction of the myocardial cells around the area of disturbance. In a first embodiment, the delivery system basically comprises a reservoir subsystem for holding the genetic material, and a catheter subsystem in communication with the reservoir subsystem for placement of the genetic material in and around the identified cardiac location. As seen in the following discussion of several preferred embodiments, the reservoir subsystem and catheter subsystem may be separate, or they may be combined. Preferably the reservoir contains up to 25 ml of a genetic material for delivery to the myocardium. In some applications, only a bolus of about 0.1-10 ml, or more preferably 1-5 ml, is delivered to the targeted areas. In other applications, such as where conduction protein is being delivered in repeated doses, 25 ml or more may be used. Also, the genetic material may be diluted in a saline solution, such as, for example, phosphate-buffered saline (PBS), the reservoir holding the diluted solution for controlled delivery. Additionally, it is to be understood that the reservoir and associated control apparatus may be either implantable or external to the body, depending upon the circumstances, e.g., whether metered doses are to be administered to the patient over a period of time, or whether the delivery of the genetic material is essentially a one time treatment.

Referring now to Fig. 1, the primary steps involved in the practice of this invention are shown in the flow diagram. As illustrated in 30, the first step is to determine the nature of the cardiac conduction disturbance, which can manifest itself in ineffective or harmful

- 11 -

conductive properties. This step can constitute diagnosis of SSS, "brady-tachy syndrome," bradycardia, tachycardia, heart block, etc. The next step, illustrated in 32, is mapping the patient's heart to determine the location, size and extent of the disturbance of problematic area.

Intracardiac electrocardiographic techniques, or electrophysiology (EP) studies, permit a detailed analysis of the mechanisms of cardiac impulse formation and conduction. The testing and mapping protocol utilized and the sites selected for recording depend upon the symptoms manifested in the individual. One skilled in the art is readily familiar with cardiac mapping techniques, such as, for example, those described in U.S. Patent 4,699,147, U.S. Patent 5,297,549, and U.S. Patent 5,397,339, all of which are incorporated by reference. The mapping techniques known to those skilled in the art will readily identify those cardiac locations encompassing cardiac cells with abnormal conduction properties. As shown in 33, the next step is to select the appropriate conduction protein genetic material.

This selection, which yields the "preselected genetic material," is dependent upon the nature of the cardiac conduction disturbance, as discussed below. The conduction protein genetic material is next prepared, as illustrated in 34, by either inserting the nucleic acid molecules encoding the appropriate conduction protein into a delivery vehicle with the appropriate regulatory elements, in the case of a recombinant nucleic acid molecule, or expressing the conduction protein from an expression vector, in the case of the conduction protein itself. As shown in 35, the next step is to prepare and load the delivery system with a therapeutically effective amount of the conduction protein genetic material. As illustrated in 37, the next step comprises administering the therapeutically effective amount to the patient by contacting the appropriate location in the heart, as determined earlier, using the delivery system described herein. An alternative method of administering the therapeutically effective amount of the conduction

protein genetic material is to directly inject the heart of the patient. The final step, shown in 38, is to evaluate the response of the patient to the treatment.

Referring now to Fig. 2, there is shown an illustrative embodiment of a delivery system useful for certain applications of this invention, e.g., where larger amounts of genetic material alone or in solution are employed. A catheter 36, preferably a transvenous catheter, includes an elongated catheter body 40, suitably an insulative outer sheath which may be made of polyurethane, Teflon, silicone, or any other acceptable biocompatible plastic. The catheter has a standard lumen (illustrated in Fig. 3) extending therethrough for the length thereof, which communicates through to a hollow helical needle element 44, which is adapted for screwing into the patient's myocardium. The outer distal end of helical element 44 is open, permitting genetic material in fluid form to be dispensed out of the end, as is discussed in more detail below in connection with Fig. 3. At the proximal end of the catheter, a fitting 46 is located, to which a Luer lock 48 is coupled. Luer lock 48 is coupled to the proximal end of elongated catheter body 40 and receives the lumen. A swivel mount 50 is mounted to Luer lock 48, allowing rotation of the catheter relative to Luer lock 52. Luer lock 52 in turn is coupled through control element 54 to a tube 58 which communicates with reservoir 55, suitably through flow control 57 and filter 56. Reservoir 55 holds a supply of the selected genetic material. Control elements 57 and 54 are used for adjustment of the pressure and flow rate, and may be mechanically or electronically controlled. Thus, unit 54 or 57 may be used to control either rate of delivery, or dosage size, or both. Control unit 54 may be programmed to automatically release predetermined doses on a timed basis. Further, for an implanted system, control unit 54 may be activated from an external programmer as illustrated at 51. Reference is made to international application published under the PCT, International

- 13 -

Publication No. WO 95/05781, incorporated herein by reference, for a more detailed description of such a reservoir and catheter combination. It is to be understood that such a system is useful for this invention only for
5 applications where larger fluid amounts are to be expressed, e.g., where a diluted saline solution is used to wash or perfuse a selected area.

Referring now to Fig. 3, there is shown in expanded detail a schematic of the distal end of the
10 catheter of Fig. 2, illustrating the interconnection of the helical element 44 with the interior of the catheter. As illustrated, the helical needle 44 is provided with an internal lumen 59 which is in communication with the internal lumen 63L of the lead formed by tube 63. In this
15 embodiment, helical element 44 may also be a pacing electrode, in which case it is formed of conductive material and welded, crimped, swaged, or connected by other means so as not to prevent fluid flow, to tip element 61. Tip element 61 in turn is electrically connected to a conductor
20 coil or coils 64, 65, which extend the length of the lead and are connected to a pacemaker. An outer membrane 60 forms the outer wall of elongated catheter body 40, shown in Fig. 2. Further referring to Fig. 3, element 44 has an outlet 75 where the genetic material may be expressed, and
25 holes or ports 76, 77, and 78 may also be utilized for providing exits for the genetic material which is supplied through lumen 59 under a pressure of up to about one atmosphere from reservoir 55 and the control elements.

In practice, a catheter 36 of the form illustrated
30 in Figs. 2 and 3 is advanced to the desired site for treatment, which site or location has been previously identified by means of cardiac mapping, as discussed above. The catheter may be guided to the indicated location by being passed down a steerable or guidable catheter having an
35 accommodating lumen, for example as disclosed in U.S. Patent No. 5,030,204; or by means of a fixed configuration guide catheter such as illustrated in U.S. Patent No. 5,104,393.

Alternately, the catheter may be advanced to the desired location within the heart by means of a deflectable stylet, as disclosed in PCT Patent Application WO 93/04724, published March 18, 1993, or by a deflectable guide wire as disclosed in U.S. Patent No. 5,060,660. In yet another embodiment, the helical element 44 may be ordinarily retracted within a sheath at the time of guiding the catheter into the patient's heart, and extended for screwing into the heart by use of a stylet. Such extensible helical arrangements are commercially available and well known in the pacing art.

It is to be understood that other forms of the reservoir subsystems and catheter subsystems are within the scope of this invention. Reservoir embodiments include, for example, drug dispensing irrigatable electrodes, such as those described in U.S. Patent 4,360,031; electrically controllable, non-occluding, body implanting drug delivery system, such as those described in U.S. Patent No. 5,041,107; implantable drug infusion reservoir such as those described in U.S. Patent No. 5,176,641; medication delivery devices such as those described in U.S. Patent 5,443,450; and infusion pumps, such as SYNCHROMED® made by Medtronic, Inc.; and osmotic pumps such as those made by Alza.

Referring now to Fig. 4, there is shown, by way of illustration, another embodiment of a delivery system having a combined catheter and reservoir, useful for applications involving delivery of a relatively small bolus of genetic material, e.g., 1-5 ml. Fig. 4 illustrates the distal end of a catheter, having a distal portion 70 which encloses an osmotic pump. See U.S. Patent 4,711,251, assigned to Medtronic, Inc., incorporated herein by reference. The pump includes an inner chamber 68 and an outer chamber 66, which chambers are separated by an impermeable membrane 67. A semi-permeable outer membrane 72 forms the outer wall of chamber 66. The tubular portion 74 of the helical member connects to lumen 74L within inner chamber 68. A conductor 80, which runs the length of the catheter, extends into the

- 15 -

inner chamber 68 and connects with extension 74E as shown at 74C to provide electrical contact through to element 44, in an application which the element 44 is used as a pacing electrode. A seal 79 is provided at the point where the
5 conductor passes through outer membrane 72 and inner membrane 67. An insulating cover 86 encompasses the conductor 80 from the point of contact with seal 79. An end cap 73, which may be integral with outer membrane 72 closes the chamber. Alternately, end cap 73 may be constructed to
10 elute a predetermined medication, such as, for example, steroids. Steroids, such as dexamethasone sodium phosphate, beclamethasone, and the like, are used to control inflammatory processes.

In this arrangement, prior to inserting the
15 catheter distal end into the patient's heart, the inner chamber 68 is charged with the genetic material which is to be dispensed into the myocardium. This may be done, for example, by simply inserting a micro needle through end cap 73, and inserting the desired bolus of genetic material into
20 chamber 68. After the chamber 68 is filled and the catheter is implanted, body fluids will enter chamber 66 through membrane 72 to impart a pressure on the inner chamber 68 via the impermeable membrane 67. This results in a dispensing of the genetic material stored within chamber
25 68 through the lumen 74L of extension 74E and the helical element 44. Although the preferred needle or element 44 is helical, additional configurations of needles or elements can also be used as known to those skilled in the art.

Still referring now to Fig. 4, there is
30 illustrated another embodiment of a catheter tip useful for delivering a small bolus of the selected genetic material. In this embodiment, the bolus of material is stored within the hollow interior of helical element 44, i.e., the interior is the reservoir. The interior reservoir is
35 maintained sealed by use of a soluble material which is normally solid, but which dissolves when subjected to body fluids for a period of time. An example of such material is

mannitol, which can be used when the delivery system is not preloaded with the conduction protein genetic material. Plugs or globules 81-85 of mannitol are illustrated (by dashed lines) in place to block the two ends of element 44, as well as the ports 76, 77, 78. In instances where the conduction protein genetic material is preloaded into the delivery system, a shape memory metal can be used in place of the mannitol. Such metals are well known to the skilled artisan. Either of these features can be combined with an osmotic pump, as described in connection with Fig. 3, where the outer chamber is filled with a saline solution which forces the genetic material out of the ports of element 44. Alternatively, the outer chamber can be filled with the genetic material, which is then forced out of the ports of element 44. Another alternate embodiment, not shown, is to use a stylet which inserted through to the distal end of the catheter, to push a piston which aids in expressing the genetic material into the myocardial cells.

Although a transvenous form of delivery system is preferred, it is to be understood that the invention can employ other methods and devices. For example, a small bolus of selected genetic material can be loaded into a micro-syringe, e.g., a 100 μ l Hamilton syringe, and applied directly from the outside of the heart.

Referring now to Fig. 5, there is shown, by way of illustration, another embodiment of a delivery system having a combined mapping catheter and delivery means. The delivery system of this embodiment comprises a catheter 90 with a distal end 91 having an opening at the distal end. The catheter 90 further comprises mapping electrode means 92 at the distal end 91. The mapping electrode means carries out the mapping of the patient's heart. Conductor means 93 electrically connects the mapping electrode means 92 to the proximal end 94 of the catheter 90. The delivery system further comprises a delivery means within the catheter. The embodiment of the delivery means illustrated in Fig. 5 is the delivery means shown in Fig. 3. However, any of the

- 17 -

delivery means described herein can be used in combination with the mapping catheter shown in Fig. 5. The catheter 90 is inserted into the patient's heart and the site located by routine mapping procedures. Once a site is identified in the heart, the mapping catheter 90 remains in place and the delivery means is then extended through the distal end 91 of the catheter 90, and the heart tissue or cells is contacted with the conduction protein genetic material. In another embodiment of the invention, the catheter 90 is a peelable introducer sheath, with two conductor means 93 electrically connecting the introducer sheath, which serves to map the heart, to electrode means 92. Once the cardiac site is mapped, the delivery means is contacted with the heart tissue, and the introducer is removed and peeled away.

Referring now to Fig. 6A, there is shown, by way of illustration, another embodiment of an implantable delivery system comprising a combined pacing lead and delivery catheter, hereinafter referred to simply as a catheter. In this embodiment, the catheter 90 is combined with a pacemaker or pulse generator (not shown) and a source of genetic material such as illustrated by pump 100 which is suitably implanted near the pacemaker. The proximal end 101 of the catheter is connected to the pacemaker in the standard fashion. The genetic material is delivered through connecting tube 102 to a proximal section 88 of the catheter, communicating with lengthwise catheter lumen illustrated at 89. Alternately, the pacemaker head may contain a reservoir and micropump, for providing delivery of the genetic material directly to the lumen 89. The main length of the catheter has an outside sheath of biocompatible insulating material 96, and at least one conductor coil 95 which communicates electrically from the pacemaker to electrode 97 at the distal tip of the catheter. The catheter further comprises an axially positioned polymeric cannula 103, having lumen 87, through at least a portion of the catheter length and positioned within coil 95, which provides an inner surface for the catheter lumen.

The cannula terminates at the distal end of the catheter, just proximal to the tip portion of electrode 97, which is illustrated as having an outer porous surface. Electrode 97 has a central opening, shown covered with the porous electrode material, through which genetic material can pass when the catheter is positioned in the patient. As shown, conductor coil 95 is electrically connected to electrode 97, and connects pace pulses and sensed cardiac signals between the pacemaker and the electrode. Of course, for a bipolar embodiment, the lead/catheter 90 carries a second electrode (not shown), suitably a ring electrode just proximal to electrode 97. Also, as illustrated, a fixation mechanism such as tines 98 are employed for fixing or anchoring the distal tip to the heart wall of the patient.

In one embodiment, pump 100 is suitably an osmotic minipump, which pumps fluid contained within through tube 102, into catheter portion 88 and through lumens 89, 87 to the tip electrode 97. As mentioned previously, the reservoir and pump may alternately be mounted in the pacemaker device itself. In either instance, the genetic material is delivered under very minimal pressure from the reservoir through the lumen of the catheter to the electrode, where it is passed through the electrode central channel to contact myocardial cells. In yet another embodiment, the lumen portion 87 provided by the cannula is utilized as the reservoir. In this embodiment, delivery may either be passive, or with the aid of a micropump (not shown). The genetic material can be preloaded into the cannula, or it can be inserted by a needle just before the catheter is introduced and positioned with the patient.

In another embodiment, as illustrated in Figure 6B, a chamber 99 is provided just proximal from eluting electrode 97, and serves as the reservoir of the genetic material. Insulating material 96 is formed from a self-sealing material such that it may be pierced with a needle, or the like, and reseal itself, thus allowing introduction of the genetic material into the chamber prior to

- 19 -

implantation. Alternately, insulating material 96 can contain a port (not shown) through which the needle inserts the genetic material. In this embodiment, delivery of the material is without a pump, i.e., passive, the material
5 draining slowly through the microporous portion of electrode 97.

As used herein, the phrase "cardiac conduction disturbance" refers to disturbances or disruptions of the normal cardiac conduction system in a mammal. Such
10 disturbances may be the result of congenital phenomena or trauma, and can manifest in conditions such as, for example, sick sinus syndrome, "brady-tachy syndrome," heart block, bradycardia, tachycardia, and other arrhythmic conditions. Manifestations of such cardiac conduction disturbances have
15 been traditionally treated by drugs, artificial conduction systems such as pacemakers, ablation therapy, or a combination thereof.

As used herein, the phrase "conduction protein genetic material" refers to recombinant nucleic acid
20 molecules encoding the conduction proteins or, alternatively, the conduction proteins themselves, which are used in the methods and delivery systems of the invention. For chronic treatment, or long term treatment, the conduction protein genetic material will be in the form of
25 recombinant nucleic acid molecules encoding the conduction protein. In contrast, for acute treatment, or short term treatment, the conduction protein genetic material will be in the form of the conduction proteins themselves. Once the conduction protein genetic material has been selected, it is
30 referred to as "predetermined genetic material."

A "recombinant nucleic acid molecule", as used herein, is comprised of an isolated conduction protein-encoding nucleotide sequence inserted into a delivery vehicle. Regulatory elements, such as the promoter and
35 polyadenylation signal, are operably linked to the nucleotide sequence encoding the conduction protein, whereby

the protein is capable of being produced when the recombinant nucleic acid molecule is introduced into a cell.

The nucleic acid molecules encoding the conduction proteins are prepared synthetically or, preferably, from isolated nucleic acid molecules, as described below. A nucleic acid is "isolated" when purified away from other cellular constituents, such as, for example, other cellular nucleic acids or proteins, by standard techniques known to those of ordinary skill in the art. The coding region of the nucleic acid molecule encoding the conduction protein can encode a full length gene product or a subfragment thereof, or a novel mutated or fusion sequence. The protein coding sequence can be a sequence endogenous to the target cell, or exogenous to the target cell. The promoter, with which the coding sequence is operably associated, may or may not be one that normally is associated with the coding sequence.

The nucleic acid molecule encoding the conduction protein is inserted into an appropriate delivery vehicle, such as, for example, an expression plasmid, cosmid, YAC vector, and the like. Almost any delivery vehicle can be used for introducing nucleic acids into the cardiovascular system, including, for example, recombinant vectors, such as one based on adenovirus serotype 5, Ad5, as set forth in French, et al., *Circulation*, 1994, 90, 2414-2424, which is incorporated herein by reference. An additional protocol for adenovirus-mediated gene transfer to cardiac cells is set forth in WO 94/11506 and in Barr, et al., *Gene Ther.*, 1994, 1, 51-58, both of which are incorporated herein by reference. Other recombinant vectors include, for example, plasmid DNA vectors, such as one derived from pGEM3 or pBR322, as set forth in Acsadi, et al., *The New Biol.*, 1991, 3, 71-81, and Gal, et al., *Lab. Invest.*, 1993, 68, 18-25, both of which are incorporated herein by reference, cDNA-containing liposomes, artificial viruses, nanoparticles, and the like. It is also contemplated that conduction proteins be injected directly into the myocardium.

- 21 -

The regulatory elements of the recombinant nucleic acid molecules of the invention are capable of directing expression in mammalian cells, specifically human cells. The regulatory elements include a promoter and a
5 polyadenylation signal. In addition, other elements, such as a Kozak region, may also be included in the recombinant nucleic acid molecule. Examples of polyadenylation signals useful to practice the present invention include, but are not limited to, SV40 polyadenylation signals and LTR
10 polyadenylation signals. In particular, the SV40 polyadenylation signal which is in pCEP4 plasmid (Invitrogen, San Diego, CA), referred to as the SV40 polyadenylation signal, can be used.

The promoters useful in constructing the
15 recombinant nucleic acid molecules of the invention may be constitutive or inducible. A constitutive promoter is expressed under all conditions of cell growth. Exemplary constitutive promoters include the promoters for the following genes: hypoxanthine phosphoribosyl transferase
20 (HPRT), adenosine deaminase, pyruvate kinase, β -actin, human myosin, human hemoglobin, human muscle creatine, and others. In addition, many viral promoters function constitutively in eukaryotic cells, and include, but are not limited to, the early and late promoters of SV40, the Mouse Mammary Tumor
25 Virus (MMTV) promoter, the long terminal repeats (LTRs) of Moloney leukemia virus, Human Immunodeficiency Virus (HIV), Cytomegalovirus (CMV) immediate early promoter, Epstein Barr Virus (EBV), Rous Sarcoma Virus (RSV), and other
retroviruses, and the thymidine kinase promoter of herpes
30 simplex virus. Other promoters are known to those of ordinary skill in the art.

Inducible promoters are expressed in the presence of an inducing agent. For example, the metallothionein promoter is induced to promote (increase) transcription in
35 the presence of certain metal ions. Other inducible promoters are known to those of ordinary skill in the art.

- 22 -

Promoters and polyadenylation signals used must be functional within the cells of the mammal. In order to maximize protein production, regulatory sequences may be selected which are well suited for gene expression in the cardiac cells into which the recombinant nucleic acid molecule is administered. For example, the promoter is preferably a cardiac tissue-specific promoter-enhancer, such as, for example, cardiac isoform troponin C (cTNC) promoter. Parmacek, et al., *J. Biol. Chem.*, 1990, 265, 15970-15976, and Parmacek, et al., *Mol. Cell Biol.*, 1992, 12, 1967-1976. In addition, codons may be selected which are most efficiently transcribed in the cell. One having ordinary skill in the art can produce recombinant nucleic acid molecules which are functional in the cardiac cells.

Genetic material can be introduced into a cell or "contacted" by a cell by, for example, transfection or transduction procedures. Transfection refers to the acquisition by a cell of new genetic material by incorporation of added nucleic acid molecules. Transfection can occur by physical or chemical methods. Many transfection techniques are known to those of ordinary skill in the art including: calcium phosphate DNA co-precipitation; DEAE-dextran DNA transfection; electroporation; naked plasmid adsorption, and cationic liposome-mediated transfection. Transduction refers to the process of transferring nucleic acid into a cell using a DNA or RNA virus. Suitable viral vectors for use as transducing agents include, but are not limited to, retroviral vectors, adeno associated viral vectors, vaccinia viruses, and Semliki Forest virus vectors.

Treatment of cells, or contacting cells, with recombinant nucleic acid molecules can take place *in vivo* or *ex vivo*. For *ex vivo* treatment, cells are isolated from an animal (preferably a human), transformed (*i.e.*, transduced or transfected *in vitro*) with a delivery vehicle containing a nucleic acid molecule encoding a conduction protein, and then administered to a recipient. Procedures for removing

- 23 -

cells from mammals are well known to those of ordinary skill in the art. In addition to cells, tissue or the whole or parts of organs may be removed, treated *ex vivo* and then returned to the patient. Thus, cells, tissue or organs may
5 be cultured, bathed, perfused and the like under conditions for introducing the recombinant nucleic acid molecules of the invention into the desired cells.

For *in vivo* treatment, cells of an animal, preferably a mammal and most preferably a human, are
10 transformed *in vivo* with a recombinant nucleic acid molecule of the invention. The *in vivo* treatment may involve systemic intravenous treatment with a recombinant nucleic acid molecule, local internal treatment with a recombinant nucleic acid molecule, such as by localized perfusion or
15 topical treatment, and the like. When performing *in vivo* administration of the recombinant nucleic acid molecule, the preferred delivery vehicles are based on noncytopathic eukaryotic viruses in which nonessential or complementable genes have been replaced with the nucleic acid sequence of
20 interest. Such noncytopathic viruses include retroviruses, the life cycle of which involves reverse transcription of genomic viral RNA into DNA with subsequent proviral integration into host cellular DNA. Retroviruses have recently been approved for human gene therapy trials. Most
25 useful are those retroviruses that are replication-deficient (*i.e.*, capable of directing synthesis of the desired proteins, but incapable of manufacturing an infectious particle). Such genetically altered retroviral expression vectors have general utility for high-efficiency
30 transduction of genes *in vivo*. Standard protocols for producing replication-deficient retroviruses (including the steps of incorporation of exogenous genetic material into a plasmid, transfection of a packaging cell line with plasmid, production of recombinant retroviruses by the packaging cell
35 line, collection of viral particles from tissue culture media, and infection of the target cells with viral particles) are provided in Kriegler, M. "Gene Transfer and

Expression, a Laboratory Manual", W.H. Freeman Co., New York (1990) and Murry, E.J. e.d. "Methods in Molecular Biology", Vol. 7, Humana Press, Inc., Clifton, New Jersey (1991).

5 A preferred virus for contacting cells in certain applications, such as in *in vivo* applications, is the adeno-associated virus, a double-stranded DNA virus. The adeno-associated virus can be engineered to be replication deficient and is capable of infecting a wide range of cell types and species. It further has advantages such as heat
10 and lipid solvent stability, high transduction frequencies in cells of diverse lineages, including hemopoietic cells, and lack of superinfection inhibition thus allowing multiple series of transductions. Recent reports indicate that the adeno-associated virus can also function in an
15 extrachromosomal fashion.

In preferred embodiments of the present invention, the recombinant nucleic acid molecules comprising nucleic acid molecules encoding the conduction proteins, or, in the alternative, the conduction proteins, are delivered to the
20 cardiac cells of the identified cardiac location, as determined by mapping procedures set forth above, using the delivery systems set forth above. Alternatively, the conduction protein genetic material is delivered to the cardiac cells of the identified cardiac location by direct
25 injection.

In preferred embodiments of the present invention, the nucleic acid molecules encoding the conduction proteins comprise the full length coding sequence cDNA of a conduction protein. Preferably, the conduction proteins are
30 the gap junction proteins; more preferably, they are the connexin proteins. Such nucleic acid molecules are described in the Fishman, et al., *J. Cell. Biol.*, 1990, 111, 589-598, and Kanter, et al., *J. Mol. Cell Cardiol.*, 1994, 26, 861-868 references, both of which are incorporated
35 herein by reference, which contain the full length coding sequence cDNA of the connexin gap junction proteins Cx43, and Cx40 and Cx45, respectively.

- 25 -

Introduction of the gap junction-encoding nucleic acid molecules or the gap junction proteins to normal cardiac cells surrounding a scar causing heart block will result in normal or enhanced conduction. Alternatively, it is proposed that introduction of the gap junction-encoding nucleic acid molecules or the gap junction proteins to abnormal cardiac cells, those cells exhibiting cardiac conduction disturbances, will result in normal or enhanced conduction properties. Determining the appropriate conduction protein genetic material, *i.e.*, determining which connexin protein is appropriate, is dependent upon the particular cardiac conduction disturbance diagnosed. For example, if the cardiac conduction pathway disturbance is a heart block or bradycardia, in which conductance is slowed or non-existent, Cx43 or Cx40, the faster connexins, is preferably used. However, if the cardiac conduction pathway disturbance is tachycardia, in which conductance is too rapid, Cx45 is preferably used.

Nucleic acid molecules comprising nucleotide sequences encoding the connexin proteins Cx40, Cx43, and Cx45 are isolated and purified according to the methods set forth in Fishman, *et al.*, *J. Cell. Biol.*, 1990, 111, 589-598, and Kanter, *et al.*, *J. Mol. Cell Cardiol.*, 1994, 26, 861-868. The nucleic acid and protein sequences of Cx40 are set forth in SEQ ID NO:1 and SEQ ID NO:2, respectively. The nucleic acid and protein sequences of Cx43 are set forth in SEQ ID NO:3 and SEQ ID NO:4, respectively. The nucleic acid and protein sequences of Cx45 are set forth in SEQ ID NO:5 and SEQ ID NO:6, respectively. It is contemplated that nucleic acid molecules comprising nucleotide sequences that are preferably at least 70% homologous, more preferably at least 80% homologous, and most preferably at least 90% homologous to the connexin nucleotide sequences described in SEQ ID NOs 1, 3 and 5, can also be used.

It is understood that minor modifications of nucleotide sequence or the primary amino acid sequence may result in proteins which have substantially equivalent or

enhanced activity as compared to the conduction proteins exemplified herein. These modifications may be deliberate, as through site-directed mutagenesis, or may be accidental such as through mutations in hosts which produce the conduction proteins. A "mutation" in a protein alters its primary structure (relative to the commonly occurring or specifically described protein) due to changes in the nucleotide sequence of the DNA which encodes it. These mutations specifically include allelic variants. Mutational changes in the primary structure of a protein can result from deletions, additions, or substitutions. A "deletion" is defined as a polypeptide in which one or more internal amino acid residues are absent as compared to the native sequence. An "addition" is defined as a polypeptide which has one or more additional internal amino acid residues as compared to the wild type protein. A "substitution" results from the replacement of one or more amino acid residues by other residues. A protein "fragment" is a polypeptide consisting of a primary amino acid sequence which is identical to a portion of the primary sequence of the protein to which the polypeptide is related.

Preferred "substitutions" are those which are conservative, i.e., wherein a residue is replaced by another of the same general type. As is well understood, naturally-occurring amino acids can be subclassified as acidic, basic, neutral and polar, or neutral and nonpolar and/or aromatic. It is generally preferred that encoded peptides differing from the native form contain substituted codons for amino acids which are from the same group as that of the amino acid replaced. Thus, in general, the basic amino acids Lys, Arg, and Histidine are interchangeable; the acidic amino acids Asp and Glu are interchangeable; the neutral polar amino acids Ser, Thr, Cys, Gln, and Asn are interchangeable; the nonpolar aliphatic acids Gly, Ala, Val, Ile, and Leu are conservative with respect to each other (but because of size, Gly and Ala are more closely related and Val, Ile and

- 27 -

Leu are more closely related), and the aromatic amino acids Phe, Trp, and Tyr are interchangeable.

While Pro is a nonpolar neutral amino acid, it represents difficulties because of its effects on
5 conformation, and substitutions by or for Pro are not preferred, except when the same or similar conformational results can be obtained. Polar amino acids which represent conservative changes include Ser, Thr, Gln, Asn; and to a lesser extent, Met. In addition, although classified in
10 different categories, Ala, Gly, and Ser seem to be interchangeable, and Cys additionally fits into this group, or may be classified with the polar neutral amino acids. Some substitutions by codons for amino acids from different classes may also be useful.

15 Once the nucleic acid molecules encoding the connexin proteins are isolated and purified according to the methods described above, recombinant nucleic acid molecules are prepared in which the desired connexin nucleic acid molecule is incorporated into a delivery vehicle by methods
20 known to those skilled in the art, as taught in, for example, Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Second Ed. Cold Spring Harbor Press (1989). Preferred delivery vehicles include, for example, plasmids (Acsadi, et al., *The New Biol.*, 1991, 3, 71-81, and Gal, et
25 al., *Lab. Invest.*, 1993, 68, 18-25, both of which are incorporated herein by reference) and adenovirus (WO 94/11506 and in Barr, et al., *Gene Ther.*, 1994, 1, 51-58, both of which are incorporated herein by reference). The nucleic acid molecules encoding connexin proteins, or
30 connexin proteins produced therefrom, are delivered to the cardiac cells of the identified cardiac location by the delivery systems of the present invention. Thus, such delivery systems of the present invention are used to contact the cardiac cells of the identified cardiac
35 location, which comprises cardiac cells having cardiac conduction disturbances, with recombinant nucleic acid molecules encoding a connexin protein, or connexin proteins.

- 28 -

Where the conduction protein genetic material is in the form of conduction proteins, such proteins can be prepared in large quantities by using various standard expression systems known to those skilled in the art.

- 5 Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Second Ed. Cold Spring Harbor Press (1989), pp. 16.1-16.55, incorporated herein by reference.

- The recombinant nucleic acid molecules or connexin proteins are preferably delivered in a pharmaceutical
10 composition. Such pharmaceutical compositions can include, for example, the recombinant nucleic acid molecule or protein in a volume of phosphate-buffered saline with 5% sucrose. In other embodiments of the invention, the recombinant nucleic acid molecule or protein is delivered
15 with suitable pharmaceutical carriers, such as those described in the most recent edition of *Remington's Pharmaceutical Sciences*, A. Osol, a standard reference text in this field. The recombinant nucleic acid molecule or protein is delivered in a therapeutically effective amount.
20 Such amount is determined experimentally and is that amount which either restores normal conduction or improves abnormal conduction of cardiac cells. The amount of recombinant nucleic acid molecule or protein is preferably between 0.01 μ g and 100 mg, more preferably between 0.1 μ g and 10 mg,
25 more preferably between 1 μ g and 1 mg, and most preferably between 10 μ g and 1 mg. A single therapeutically effective amount is referred to as a bolus. Where adenovirus vectors are used, the amount of recombinant nucleic acid molecule is preferably between 10^7 plaque forming units (pfu) and 10^{15}
30 pfu, more preferably between 10^8 pfu and 10^{14} pfu, and most preferably between 10^9 pfu and 10^{12} pfu. A single therapeutically effective amount of conduction protein genetic material is referred to as a bolus. In some
35 embodiments of the present invention, the delivery of the recombinant nucleic acid molecules or proteins is combined with steroid elution, such as with dexamethasone sodium

- 29 -

phosphate, beclamethasone, and the like, to control inflammatory processes.

The following examples are meant to be exemplary of the preferred embodiments of the invention and are not
5 meant to be limiting.

EXAMPLES

Example 1: Isolation and Purification of Nucleic Acid Molecules Encoding the Connexin Proteins

Nucleic acid molecules encoding Cx43, Cx40, and
10 Cx45 are isolated and purified according to general methods well known to those skilled in the art. Briefly, total cellular RNA is isolated and purified (Chomczynsky, et al., *Anal. Biochem.*, 1987, 162, 156-159) from heart tissue, cardiac transplantation donors, or from salvaged tissue, and
15 selected for poly(A) RNA (Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Second Ed. Cold Spring Harbor Press (1989), pp. 7.26-7.29). cDNA corresponding to the connexin proteins is prepared from the poly(A) cardiac RNA by reverse transcription using a GENEAMP™ PCR kit (Perkin
20 Elmer Cetus, Norwalk, CT), or the like, using random hexamers according to the manufacturer's instructions. The specific connexin nucleic acid molecules are amplified by the polymerase chain reaction (PCR), also using the GENEAMP™ PCR kit, or the like, using forward and reverse primers
25 specific for each of the different connexin proteins, according to the manufacturer's instructions. For example, the forward primer for Cx43 can be 5'-ATGCCTGACTGGACCGCCTTAGGC-3' (SEQ ID NO:7), and the reverse primer can be 5'-GATCTCGAGGTCATCAGGCCGAGG-3' (SEQ ID NO:8).
30 For example, the forward primer for Cx45 can be 5'-ATGAGTTGGAGCTTTCTGACTCGC-3' (SEQ ID NO:9), and the reverse primer can be 5'-AATCCAGACAGAGTTCTTCCCATC-3' (SEQ ID NO:10). For example, the forward primer for Cx40 can be 5'-ATGGGCGATTGGAGCTTCCTGGGA-3' (SEQ ID NO:11), and the reverse
35 primer can be 5'-CACTGATAGGTCATCTGACCTTGC-3' (SEQ ID NO:12). It is understood that additional primers can be used for amplification as determined by those skilled in the art.

These primers may be preceded at the 5' terminus by nucleotide sequences containing endonuclease restriction sites for easy incorporation into vectors. The specific connexin nucleic acid molecules can also be amplified by PCR from human genomic DNA (Stratagene, San Diego, CA). After cutting the PCR products with the appropriate restriction endonuclease(s), the PCR products are purified by phenol:chloroform extractions, or using commercial purification kits, such as, for example, MAGIC™ Minipreps DNA Purification System (Promega, Madison, WI). The specific nucleotide sequence of the PCR products is determined by conventional DNA sequencing procedures, and the identity of the PCR products confirmed by comparison to the published sequences for the connexin proteins.

15 **Example 2: Insertion of Connexin cDNA into Delivery Vehicles**

Preferably, connexin cDNA is inserted into either plasmid or adenoviral vectors. Plasmid vectors include for example, pGEM3 or pBR322, as set forth in Acsadi, et al., *The New Biol.*, 1991, 3, 71-81, and Gal, et al., *Lab. Invest.*, 1993, 68, 18-25. Adenoviral vectors include for example, adenovirus serotype 5, Ad5, as set forth in French, et al., *Circulation*, 1994, 90, 2414-2424.

Preferably, the primers used to amplify the connexin nucleic acid molecules are designed with unique endonuclease restriction sites located at the 5' terminus. In the absence of such design, polylinker arms, containing unique restriction sites, can be ligated thereto. After cutting the purified PCR products with the appropriate restriction endonuclease(s), the plasmid vector, comprising a polylinker, is also cut with the same restriction endonuclease(s), affording the connexin nucleic acid molecule a site at which to ligate. In a similar manner, recombinant adenovirus (Gluzman, et al., in *Eukaryotic Viral Vectors*, Gluzman, ed., Cold Spring Harbor Press, 1982, pp.187-192, and French, et al., *Circulation*, 1994, 90, 2414-2424) containing connexin cDNA molecules are prepared in

- 31 -

accordance with standard techniques well known to those skilled in the art.

It is contemplated that variations of the above-described invention may be constructed that are consistent
5 with the spirit of the invention.

- 32 -

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANTS: Stokes, Kenneth
Morissette, Josée(ii) TITLE OF INVENTION: SYSTEM FOR GENETICALLY TREATING CARDIAC
CONDUCTION DISTURBANCES

(iii) NUMBER OF SEQUENCES: 12

(iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz & Norris LLP
(B) STREET: One Liberty Place - 46th Floor
(C) CITY: Philadelphia
(D) STATE: PA
(E) COUNTRY: U.S.A.
(F) ZIP: 19103(v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: WordPerfect 6.1(vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER: N/A
(B) FILING DATE: Herewith
(C) CLASSIFICATION:(viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Paul K. Legaard
(B) REGISTRATION NUMBER: 38,534
(C) REFERENCE/DOCKET NUMBER: MEDT-0059(ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: (215) 568-3100
(B) TELEFAX: (215) 568-3439

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1074 bases
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

ATG GGC GAT TGG AGC TTC CTG GGA AAT TTC CTG GAG GAA GTA CAC	45
Met Gly Asp Trp Ser Phe Leu Gly Asn Phe Leu Glu Glu Val His	15
1 5 10	
AAG CAC TCG ACC GTG GTA GGC AAG GTC TGG CTC ACT GTC CTC TTC	90
Lys His Ser Thr Val Val Gly Lys Val Trp Leu Thr Val Leu Phe	30
20 25	
ATA TTC CGT ATG CTC GTG CTG GGC ACA GCT GCT GAG TCT ACC TGG	135
Ile Phe Arg Met Leu Val Leu Gly Thr Ala Ala Glu Ser Thr Trp	45
35 40	
GGG GAT GAG CAG GCT GAT TTC CGG TGT GAT ACG ATT CAG CCT GGC	180
Gly Asp Glu Gln Ala Asp Phe Arg Cys Asp Thr Ile Gln Pro Gly	60
50 55	
TGC CAC AAT GTC TGC TAC GAC CAG GCT TTC CCC ATC TCC CAC ATT	225
Cys His Asn Val Cys Tyr Asp Gln Ala Phe Pro Ala Ser His Ile	75
65 70	

- 33 -

CGC TAC TGG GTG CTG CAG ATC ATC TTC GTC TCT ACG CCC TCT CTG	270
Arg Tyr Trp Val Leu Gln Ile Ile Phe Val Ser Thr Pro Ser Leu	
80 85 90	
GTG TAC ATG GGC CAC GCC ATG CAC ACT GTG CGC ATG CAG GAG AAG	315
Val Tyr Met Gly His Ala Met His Thr Val Arg Met Gln Glu Lys	
95 100 105	
CGC AAG CTA CGG GAG GCC GAG AGG GCC AAA GAG GTC CGG GGC TCT	360
Arg Lys Leu Arg Glu Ala Glu Arg Ala Lys Glu Val Arg Gly Ser	
110 115 120	
GGC TCT TAC GAG TAC CCG GTG GCA GAG AAG GCA GAA CTG TCC TGC	405
Gly Ser Tyr Glu Tyr Pro Val Ala Glu Lys Ala Glu Leu Ser Cys	
125 130 135	
TGG GAG GAA GGG AAT GGA AGG ATT GCC CTC CAG GGC ACT CTG CTC	450
Trp Glu Glu Glu Asn Gly Arg Ile Ala Leu Gln Gly Thr Leu Leu	
140 145 150	
AAC ACC TAT GTG TGC AGC ATC CTG ATC CGC ACC ACC ATG GAG GTG	495
Asn Thr Tyr Val Cys Ser Ile Leu Ile Arg Thr Thr Met Glu Val	
155 160 165	
GGC TTC ATT GTG GGC CAG TAC TTC ATC TAC GGA ATC TTC CTG ACC	540
Gly Phe Ile Val Gly Gln Tyr Phe Ile Tyr Gly Ile Phe Leu Thr	
170 175 180	
ACC CTG CAT GTC TGC CGC AGG AGT CCC TGT CCC CAC CCG GTC AAC	585
Thr Leu His Val Cys Arg Arg Ser Pro Cys Pro His Pro Val Asn	
185 190 195	
TGT TAC GTA TCC CGG CCC ACA GAG AAG AAT GTC TTC ATT GTC TTT	630
Cys Tyr Val Ser Arg Pro Thr Glu Lys Asn Val Phe Ile Val Phe	
200 205 210	
ATG CTG GCT GTG GCT GCA CTG TCC CTC CTC CTT AGC CTG GCT GAA	675
Met Leu Ala Val Ala Ala Leu Ser Leu Leu Leu Ser Leu Ala Glu	
215 220 225	
CTC TAC CAC CTG GGC TGG AAG AAG ATC AGA CAG CGA TTT GTC AAA	720
Leu Tyr His Leu Gly Trp Lys Lys Ile Arg Gln Arg Phe Val Lys	
230 235 240	
CCG CGG CAG TAC ATG GCT AAG TGC CAG CTT TCT GGC CCT CTG TGG	765
Pro Arg Gln Trp Met Ala Lys Cys Gln Leu Ser Gly Pro Leu Trp	
245 250 255	
GCT ATA GTC CAG AGC TGC ACA CCA CCC CCC GAC TTT AAT CAG TGC	810
Ala Ile Val Gln Ser Cys Thr Pro Pro Pro Asp Phe Asn Gln Cys	
260 265 270	
CTG GAG AAT GGT CCT GGG GGA AAA TTC TTC AAT CCC TTC AGC AAT	855
Leu Glu Asn Gly Pro Gly Gly Lys Phe Phe Asn Pro Phe Ser Asn	
275 280 285	
AAT ATG GCC TCC CAA CAA AAC ACA GAC AAC CTG GTC ACC GAG CAA	900
Asn Met Ala Ser Gln Gln Asn Thr Asp Asn Leu Val Thr Glu Gln	
290 295 300	
GTA CGA GGT CAG GAG CAG ACT CCT GGG GAA GGT TTC ATC CAG GTT	945
Val Arg Gly Gln Glu Gln Thr Pro Gly Glu Gly Phe Ile Gln Val	
305 310 315	

- 34 -

CGT TAT GGC CAG AAG CCT GAG GTG CCC AAT GGA GTC TCA CCA GGT 990
 Arg Tyr Gly Gln Lys Pro Glu Val Pro Asn Gly Val Ser Pro Gly 330
 320 325

CAC CGC CTT CCC CAT GGC TAT CAT AGT GAC AAG CGA CGT CTT AGT 1035
 His Arg Leu Pro His Gly Tyr His Ser Asp Lys Arg Arg Leu Ser 345
 335 340

AAG GCC AGC AGC AAG GCA AGG TCA GAT GAC CTA TCA GTG 1074
 Lys Ala Ser Ser Lys Ala Arg Ser Asp Asp Leu Ser Val 355
 350

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 358 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: unknown

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met Gly Asp Trp Ser Phe Leu Gly Asn Phe Leu Glu Glu Val His 15
 1 5 10

Lys His Ser Thr Val Val Gly Lys Val Trp Leu Thr Val Leu Phe 30
 20 25

Ile Phe Arg Met Leu Val Leu Gly Thr Ala Ala Glu Ser Thr Trp 45
 35 40

Gly Asp Glu Gln Ala Asp Phe Arg Cys Asp Thr Ile Gln Pro Gly 60
 50 55

Cys His Asn Val Cys Tyr Asp Gln Ala Phe Pro Ala Ser His Ile 75
 65 70

Arg Tyr Trp Val Leu Gln Ile Ile Phe Val Ser Thr Pro Ser Leu 90
 80 85

Val Tyr Met Gly His Ala Met His Thr Val Arg Met Gln Glu Lys 105
 95 100

Arg Lys Leu Arg Glu Ala Glu Arg Ala Lys Glu Val Arg Gly Ser 120
 110 115

Gly Ser Tyr Glu Tyr Pro Val Ala Glu Lys Ala Glu Leu Ser Cys 135
 125 130

Trp Glu Glu Glu Asn Gly Arg Ile Ala Leu Gln Gly Thr Leu Leu 150
 140 145

Asn Thr Tyr Val Cys Ser Ile Leu Ile Arg Thr Thr Met Glu Val 165
 155 160

Gly Phe Ile Val Gly Gln Tyr Phe Ile Tyr Gly Ile Phe Leu Thr 180
 170 175

Thr Leu His Val Cys Arg Arg Ser Pro Cys Pro His Pro Val Asn 195
 185 190

Cys Tyr Val Ser Arg Pro Thr Glu Lys Asn Val Phe Ile Val Phe 210
 200 205

Met Leu Ala Val Ala Ala Leu Ser Leu Leu Leu Ser Leu Ala Glu 225
 215 220

Leu Tyr His Leu Gly Trp Lys Lys Ile Arg Gln Arg Phe Val Lys 240
 230 235

- 35 -

Pro	Arg	Gln	Trp	Met	Ala	Lys	Cys	Gln	Leu	Ser	Gly	Pro	Leu	Trp	
				245					250					255	
Ala	Ile	Val	Gln	Ser	Cys	Thr	Pro	Pro	Pro	Asp	Phe	Asn	Gln	Cys	
				260					265					270	
Leu	Glu	Asn	Gly	Pro	Gly	Gly	Lys	Phe	Phe	Asn	Pro	Phe	Ser	Asn	
				275					280					285	
Asn	Met	Ala	Ser	Gln	Gln	Asn	Thr	Asp	Asn	Leu	Val	Thr	Glu	Gln	
				290					295					300	
Val	Arg	Gly	Gln	Glu	Gln	Thr	Pro	Gly	Glu	Gly	Phe	Ile	Gln	Val	
				305					310					315	
Arg	Tyr	Gly	Gln	Lys	Pro	Glu	Val	Pro	Asn	Gly	Val	Ser	Pro	Gly	
				320					325					330	
His	Arg	Leu	Pro	His	Gly	Tyr	His	Ser	Asp	Lys	Arg	Arg	Leu	Ser	
				335					340					345	
Lys	Ala	Ser	Ser	Lys	Ala	Arg	Ser	Asp	Asp	Leu	Ser	Val			
				350					355						

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1146 bases

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

ATG	GGT	GAC	TGG	AGC	GCC	TTA	GGC	AAA	CTC	CTT	GAC	AAG	GTT	CAA	45
Met	Gly	Asp	Trp	Ser	Ala	Leu	Gly	Lys	Leu	Leu	Asp	Lys	Val	Gln	
1				5					10					15	
GCC	TAC	TCA	ACT	GCT	GGA	GGG	AAG	GTG	TGG	CTG	TCA	GTA	CTT	TTC	90
Ala	Tyr	Ser	Thr	Ala	Gly	Gly	Lys	Val	Trp	Leu	Ser	Val	Leu	Phe	
				20					25					30	
ATT	TTC	CGA	ATC	CTG	CTG	CTG	GGG	ACA	GCG	GTT	GAG	TCA	GCC	TGG	135
Ile	Phe	Arg	Ile	Leu	Leu	Leu	Gly	Thr	Ala	Val	Glu	Ser	Ala	Trp	
				35					40					45	
GGA	GAT	GAG	CAG	TCT	GCC	TTT	CGT	TGT	AAC	ACT	CAG	CAA	CCT	GGT	180
Gly	Asp	Glu	Gln	Ser	Ala	Phe	Arg	Cys	Asn	Thr	Gln	Gln	Pro	Gly	
				50					55					60	
TGT	GAA	AAT	GTC	TGC	TAT	GAC	AAG	TCT	TTC	CCA	ATC	TCT	CAT	GTG	225
Cys	Glu	Asn	Val	Cys	Tyr	Asp	Lys	Ser	Phe	Pro	Ile	Ser	His	Val	
				65					70					75	
CGC	TTC	TGG	GTC	CTG	CAG	ATC	ATA	TTT	GTG	TCT	GTA	CCC	ACA	CTC	270
Arg	Phe	Trp	Val	Leu	Gln	Ile	Ile	Phe	Val	Ser	Val	Pro	Thr	Leu	
				80					85					90	
TTG	TAC	CTG	GCT	CAT	GTG	TTC	TAT	GTG	ATG	CGA	AAG	GAA	GAG	AAA	315
Leu	Tyr	Leu	Ala	His	Val	Phe	Tyr	Val	Met	Arg	Lys	Glu	Glu	Lys	
				95					100					105	
CTG	AAC	AAG	AAA	GAG	GAA	GAA	CTC	AAG	GTT	GCC	CAA	ACT	GAT	GGT	360
Leu	Asn	Lys	Lys	Glu	Glu	Glu	Leu	Lys	Val	Ala	Gln	Thr	Asp	Gly	
				110					115					120	
GTC	AAT	GTG	GAC	ATG	CAC	TTG	AAG	CAG	ATT	GAG	ATA	AAG	AAG	TTC	405
Val	Asn	Val	Asp	Met	His	Leu	Lys	Gln	Ile	Glu	Ile	Lys	Lys	Phe	
				125					130					135	

WO 98/02150

- 36 -

AAG TAC GGT ATT GAA GAG CAT GGT AAG GTG AAA ATG CGA GGG GGG 450
 Lys Tyr Gly Ile Glu Glu His Gly Lys Val Lys Met Arg Gly Gly
 140 145 150

TTG CTG CGA ACC TAC ATC ATC AGT ATC CTC TTC AAG TCT ATC TTT 495
 Leu Leu Arg Thr Tyr Ile Ile Ser Ile Leu Phe Lys Ser Ile Phe
 155 160 165

GAG GTG GCC TTC TTG CTG ATC CAG TGG TAC ATC TAT GGA TTC AGC 540
 Glu Val Ala Phe Leu Leu Ile Gln Trp Tyr Ile Tyr Gly Phe Ser
 170 175 180

TTG AGT GCT GTT TAC ACT TGC AAA AGA GAT CCC TGC CCA CAT CAG 585
 Leu Ser Ala Val Tyr Thr Cys Lys Arg Asp Pro Cys Pro His Gln
 185 190 195

GTG GAC TGT TTC CTC TCT CGC CCC ACG GAG AAA ACC ATC TTC ATC 630
 Val Asp Cys Phe Leu Ser Arg Pro Thr Glu Lys Thr Ile Phe Ile
 200 205 210

ATC TTC ATG CTG GTG GTG TCC TTG GTG TCC CTG GCC TTG AAT ATC 675
 Ile Phe Met Leu Val Val Ser Leu Val Ser Leu Ala Leu Asn Ile
 215 220 225

ATT GAA CTC TTC TAT GTT TTC TTC AAG GGC GTT AAG GAT CGG GTT 720
 Ile Glu Leu Phe Tyr Val Phe Phe Lys Gly Val Lys Asp Arg Val
 230 235 240

AAG GGA AAG AGC GAC CCT TAC CAT GCG ACC AGT GGT GCG CTG AGC 765
 Lys Gly Lys Cys Asp Pro Tyr His Ala Thr Ser Gly Ala Leu Ser
 245 250 255

CCT GCC AAA GAC TGT GGG TCT CAA AAA TAT GCT TAT TTC AAT GGC 810
 Pro Ala Lys Asp Cys Gly Ser Gln Lys Tyr Ala Tyr Phe Asn Gly
 260 265 270

TGC TCC TCA CCA ACC GCT CCC CTC TCG CCT ATG TCT CCT CCT GGG 855
 Cys Ser Ser Pro Thr Ala Pro Leu Ser Pro Met Ser Pro Pro Gly
 275 280 285

TAC AAG CTG GTT ACT GGC GAC AGA AAC AAT TCT TCT TGC CGC AAT 900
 Tyr Lys Leu Val Thr Gly Asp Arg Asn Asn Ser Ser Cys Arg Asn
 290 295 300

TAC AAC AAG CAA GCA AGT GAG CAA AAC TGG GCT AAT TAC AGT GCA 945
 Tyr Asn Lys Gln Ala Ser Glu Gln Asn Trp Ala Asn Tyr Ser Ala
 305 310 315

GAA CAA AAT CGA ATG GGG CAG GCG GGA AGC ACC ATC TCT AAC TCC 990
 Glu Gln Asn Arg Met Gly Gly Ala Gly Ser Thr Ile Ser Asn Ser
 320 325 330

CAT GCA CAG CCT TTT GAT TTC CCC GAT GAT AAC CAG AAT TCT AAA 1035
 His Ala Gln Pro Phe Asp Phe Pro Asp Asp Asn Gln Asn Ser Lys
 335 340 345

AAA CTA GCT GCT GGA CAT GAA TTA CAG CCA CTA GCC ATT GTG GAC 1080
 Lys Leu Ala Ala Gly His Glu Leu Gln Pro Leu Ala Ile Val Asp
 350 355 360

CAG CGA CCT TCA AGC AGA GCC AGC AGT CGT GCC AGC AGC AGA CCT 1125
 Gln Arg Pro Ser Ser Arg Ala Ser Ser Arg Ala Ser Ser Arg Pro
 365 370 375

CGG CCT GAT GAC CTG GAG ATC 1146
 Arg Pro Asp Asp Leu Glu Ile
 380

- 37 -

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 382 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: unknown

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Met	Gly	Asp	Trp	Ser	Ala	Leu	Gly	Lys	Leu	Leu	Asp	Lys	Val	Gln	1	5	10	15
Ala	Tyr	Ser	Thr	Ala	Gly	Gly	Lys	Val	Trp	Leu	Ser	Val	Leu	Phe	20	25	30	
Ile	Phe	Arg	Ile	Leu	Leu	Leu	Gly	Thr	Ala	Val	Glu	Ser	Ala	Trp	35	40	45	
Gly	Asp	Glu	Gln	Ser	Ala	Phe	Arg	Cys	Asn	Thr	Gln	Gln	Pro	Gly	50	55	60	
Cys	Glu	Asn	Val	Cys	Tyr	Asp	Lys	Ser	Phe	Pro	Ile	Ser	His	Val	65	70	75	
Arg	Phe	Trp	Val	Leu	Gln	Ile	Ile	Phe	Val	Ser	Val	Pro	Thr	Leu	80	85	90	
Leu	Tyr	Leu	Ala	His	Val	Phe	Tyr	Val	Met	Arg	Lys	Glu	Glu	Lys	95	100	105	
Leu	Asn	Lys	Lys	Glu	Glu	Glu	Leu	Lys	Val	Ala	Gln	Thr	Asp	Gly	110	115	120	
Val	Asn	Val	Asp	Met	His	Leu	Lys	Gln	Ile	Glu	Ile	Lys	Lys	Phe	125	130	135	
Lys	Tyr	Gly	Ile	Glu	Glu	His	Gly	Lys	Val	Lys	Met	Arg	Gly	Gly	140	145	150	
Leu	Leu	Arg	Thr	Tyr	Ile	Ile	Ser	Ile	Leu	Phe	Lys	Ser	Ile	Phe	155	160	165	
Glu	Val	Ala	Phe	Leu	Leu	Ile	Gln	Trp	Tyr	Ile	Tyr	Gly	Phe	Ser	170	175	180	
Leu	Ser	Ala	Val	Tyr	Thr	Cys	Lys	Arg	Asp	Pro	Cys	Pro	His	Gln	185	190	195	
Val	Asp	Cys	Phe	Leu	Ser	Arg	Pro	Thr	Glu	Lys	Thr	Ile	Phe	Ile	200	205	210	
Ile	Phe	Met	Leu	Val	Val	Ser	Leu	Val	Ser	Leu	Ala	Leu	Asn	Ile	215	220	225	
Ile	Glu	Leu	Phe	Tyr	Val	Phe	Phe	Lys	Gly	Val	Lys	Asp	Arg	Val	230	235	240	
Lys	Gly	Lys	Cys	Asp	Pro	Tyr	His	Ala	Thr	Ser	Gly	Ala	Leu	Ser	245	250	255	
Pro	Ala	Lys	Asp	Cys	Gly	Ser	Gln	Lys	Tyr	Ala	Tyr	Phe	Asn	Gly	260	265	270	
Cys	Ser	Ser	Pro	Thr	Ala	Pro	Leu	Ser	Pro	Met	Ser	Pro	Pro	Gly	275	280	285	

WO 98/02150

- 38 -

Tyr Lys Leu Val Thr Gly Asp Arg Asn Asn Ser Ser Cys Arg Asn 300
 290 295
 Tyr Asn Lys Gln Ala Ser Glu Gln Asn Trp Ala Asn Tyr Ser Ala 315
 305 310
 Glu Gln Asn Arg Met Gly Gly Ala Gly Ser Thr Ile Ser Asn Ser 330
 320 325
 His Ala Gln Pro Phe Asp Phe Pro Asp Asp Asn Gln Asn Ser Lys 345
 335 340
 Lys Leu Ala Ala Gly His Glu Leu Gln Pro Leu Ala Ile Val Asp 360
 350 355
 Gln Arg Pro Ser Ser Arg Ala Ser Ser Arg Ala Ser Ser Arg Pro 375
 365 370
 Arg Pro Asp Asp Leu Glu Ile 380

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1188 bases
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

ATG AGT TGG AGC TTT CTG ACT CGC CTG CTA GAG GAG ATT CAC AAC	45
Met Ser Trp Ser Phe Leu Thr Arg Leu Leu Glu Glu Ile His Asn	15
1 5 10	
CAT TCC ACA TTT GTG GGG AAG ATC TGG CTC ACT GTT CTG ATT GTC	90
His Ser Thr Phe Val Gly Lys Ile Trp Leu Thr Val Leu Ile Val	30
20 25	
TTC CGG ATC GTC CTT ACA GCT GTA GGA GGA GAA TCC ATC TAT TAC	135
Phe Arg Ile Val Leu Thr Ala Val Gly Gly Glu Ser Ile Tyr Tyr	45
35 40	
GAT GAG CAA AGC AAA TTT GTG TGC AAC ACA GAA CAG CCG GGC TGT	180
Asp Glu Gln Ser Lys Phe Val Cys Asn Thr Glu Gln Pro Gly Cys	60
50 55	
GAG AAT GTC TGT TAT GAT GCG TTT GCA CCT CTC TCC CAT GTA CGC	225
Glu Asn Val Cys Tyr Asp Ala Phe Ala Pro Leu Ser His Val Arg	75
65 70	
TTC TGG GTG TTC CAG ATC ATC CTG GTG GCA ACT CCC TCT GTG ATG	270
Phe Trp Val Phe Gln Ile Ile Leu Val Ala Thr Pro Ser Val Met	90
80 85	
TAC CTG GGC TAT GCT ATC CAC AAG ATT GCC AAA ATG GAG CAC GGT	315
Tyr Leu Gly Tyr Ala Ile His Lys Ile Ala Lys Met Glu His Gly	105
95 100	
GAA GCA GAC AAG AAG GCA GCT CGG AGC AAG CCC TAT GCA ATG CGC	360
Glu Ala Asp Lys Lys Ala Ala Arg Ser Lys Pro Tyr Ala Met Arg	120
110 115	
TGG AAA CAA CAC CGG GCT CTG GAA GAA ACG GAG GAG GAC AAC GAA	405
Trp Lys Gln His Arg Ala Leu Glu Glu Thr Glu Glu Asp Asn Glu	135
125 130	

- 39 -

GAG GAT CCT ATG ATG TAT CCA GAG ATG GAG TTA GAA AGT GAT AAG	450
Glu Asp Pro Met Met Tyr Pro Glu Met Glu Leu Glu Ser Asp Lys	
140 145 150	
GAA AAT AAA GAG CAG AGC CAA CCC AAA CCT AAG CAT GAT GGC CGA	495
Glu Asn Lys Glu Gln Ser Gln Pro Lys Pro Lys His Asp Gly Arg	
155 160 165	
CGA CGG ATT CGG GAA GAT GGG CTC ATG AAA ATC TAT GTG CTG CAG	540
Arg Arg Ile Arg Glu Asp Gly Leu Met Lys Ile Tyr Val Leu Gln	
170 175 180	
TTG CTG GCA AGG ACC GTG TTT GAG GTG GGT TTT CTG ATA GGG CAG	585
Leu Leu Ala Arg Thr Val Phe Glu Val Gly Phe Leu Ile Gly Gln	
185 190 195	
TAT TTT CTG TAT GGC TTC CAA GTC CAC CCG TTT TAT GTG TGC AGC	630
Tyr Phe Leu Tyr Gly Phe Gln Val His Pro Phe Tyr Val Cys Ser	
200 205 210	
AGA CTT CCT TGT CCT CAT AAG ATA GAC TGC TTT ATT TCT AGA CCC	675
Arg Leu Pro Cys Pro His Lys Ile Asp Cys Phe Ile Ser Arg Pro	
215 220 225	
ACT GAA AAG ACC ATC TTC CTT CTG ATA ATG TAT GGT GTT ACA GGC	720
Thr Glu Lys Thr Ile Phe Leu Leu Ile Met Tyr Gly Val Thr Gly	
230 235 240	
CTT TGC CTC TTG CTT AAC ATT TGG GAG ATG CTT CAT TTA GGG TTT	765
Leu Cys Leu Leu Leu Asn Ile Trp Glu Met Leu His Leu Gly Phe	
245 250 255	
GGG ACC ATT CGA GAC TCA CTA AAC AGT AAA AGG AGG GAA CTT GAG	810
Gly Thr Ile Arg Asp Ser Leu Asn Ser Lys Arg Arg Glu Leu Glu	
260 265 270	
GAT CCG GGT GCT TAT AAT TAT CCT TTC ACT TGG AAT ACA CCA TCT	855
Asp Pro Gly Ala Tyr Asn Tyr Pro Phe Thr Trp Asn Thr Pro Ser	
275 280 285	
GCT CCC CCT GGC TAT AAC ATT GCT GTC AAA CCA GAT CAA ATC CAG	900
Ala Pro Pro Gly Tyr Asn Ile Ala Val Lys Pro Asp Gln Ile Gln	
290 295 300	
TAC ACC GAA CTG TCC AAT GCT AAG ATC GCC TAC AAG CAA AAC AAG	945
Tyr Thr Glu Leu Ser Asn Ala Lys Ile Ala Tyr Lys Gln Asn Lys	
305 310 315	
GCC AAC ACA GCC CAG GAA CAG CAG TAT GGC AGC CAT GAG GAG AAC	990
Ala Asn Thr Ala Gln Glu Gln Gln Tyr Gly Ser His Glu Glu Asn	
320 325 330	
CTC CCA GCT GAC CTG GAG GCT CTG CAG CGG GAG ATC AGG ATG GCT	1035
Leu Pro Ala Asp Leu Glu Ala Leu Gln Arg Glu Ile Arg Met Ala	
335 340 345	
CAG GAA CGC TTG GAT CTG GCA GTT CAG GCC TAC AGT CAC CAA AAC	1080
Gln Glu Arg Leu Asp Leu Ala Val Gln Ala Tyr Ser His Gln Asn	
350 355 360	
AAC CCT CAT GGT CCC CGG GAG AAG AAG GCC AAA GTG GGG TCC AAA	1125
Asn Pro His Gly Pro Arg Glu Lys Lys Ala Lys Val Gly Ser Lys	
365 370 375	
GCT GGG TCC AAC AAA AGC ACT GCC AGT AGC AAA TCA GGG GAT GGG	1170
Ala Gly Ser Asn Lys Ser Thr Ala Ser Ser Lys Ser Gly Asp Gly	
380 385 390	

- 40 -

AAG AAC TCT GTC TGG ATT 1188
 Lys Asn Ser Val Trp Ile
 395

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 396 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: unknown

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

Met	Ser	Trp	Ser	Phe	Leu	Thr	Arg	Leu	Leu	Glu	Glu	Ile	His	Asn	15
1				5					10						
His	Ser	Thr	Phe	Val	Gly	Lys	Ile	Trp	Leu	Thr	Val	Leu	Ile	Val	30
				20					25						
Phe	Arg	Ile	Val	Leu	Thr	Ala	Val	Gly	Gly	Glu	Ser	Ile	Tyr	Tyr	45
				35					40						
Asp	Glu	Gln	Ser	Lys	Phe	Val	Cys	Asn	Thr	Glu	Gln	Pro	Gly	Cys	60
				50					55						
Glu	Asn	Val	Cys	Tyr	Asp	Ala	Phe	Ala	Pro	Leu	Ser	His	Val	Arg	75
				65					70						
Phe	Trp	Val	Phe	Gln	Ile	Ile	Leu	Val	Ala	Thr	Pro	Ser	Val	Met	90
				80					85						
Tyr	Leu	Gly	Tyr	Ala	Ile	His	Lys	Ile	Ala	Lys	Met	Glu	His	Gly	105
				95					100						
Glu	Ala	Asp	Lys	Lys	Ala	Ala	Arg	Ser	Lys	Pro	Tyr	Ala	Met	Arg	120
				110					115						
Trp	Lys	Gln	His	Arg	Ala	Leu	Glu	Glu	Thr	Glu	Glu	Asp	Asn	Glu	135
				125					130						
Glu	Asp	Pro	Met	Met	Tyr	Pro	Glu	Met	Glu	Leu	Glu	Ser	Asp	Lys	150
				140					145						
Glu	Asn	Lys	Glu	Gln	Ser	Gln	Pro	Lys	Pro	Lys	His	Asp	Gly	Arg	165
				155					160						
Arg	Arg	Ile	Arg	Glu	Asp	Gly	Leu	Met	Lys	Ile	Tyr	Val	Leu	Gln	180
				170					175						
Leu	Leu	Ala	Arg	Thr	Val	Phe	Glu	Val	Gly	Phe	Leu	Ile	Gly	Gln	195
				185					190						
Tyr	Phe	Leu	Tyr	Gly	Phe	Gln	Val	His	Pro	Phe	Tyr	Val	Cys	Ser	210
				200					205						
Arg	Leu	Pro	Cys	Pro	His	Lys	Ile	Asp	Cys	Phe	Ile	Ser	Arg	Pro	225
				215					220						
Thr	Glu	Lys	Thr	Ile	Phe	Leu	Leu	Ile	Met	Tyr	Gly	Val	Thr	Gly	240
				230					235						
Leu	Cys	Leu	Leu	Leu	Asn	Ile	Trp	Glu	Met	Leu	His	Leu	Gly	Phe	255
				245					250						
Gly	Thr	Ile	Arg	Asp	Ser	Leu	Asn	Ser	Lys	Arg	Arg	Glu	Leu	Glu	270
				260					265						

- 41 -

Asp	Pro	Gly	Ala	Tyr	Asn	Tyr	Pro	Phe	Thr	Trp	Asn	Thr	Pro	Ser	275	280	285
Ala	Pro	Pro	Gly	Tyr	Asn	Ile	Ala	Val	Lys	Pro	Asp	Gln	Ile	Gln	290	295	300
Tyr	Thr	Glu	Leu	Ser	Asn	Ala	Lys	Ile	Ala	Tyr	Lys	Gln	Asn	Lys	305	310	315
Ala	Asn	Thr	Ala	Gln	Glu	Gln	Gln	Tyr	Gly	Ser	His	Glu	Glu	Asn	320	325	330
Leu	Pro	Ala	Asp	Leu	Glu	Ala	Leu	Gln	Arg	Glu	Ile	Arg	Met	Ala	335	340	345
Gln	Glu	Arg	Leu	Asp	Leu	Ala	Val	Gln	Ala	Tyr	Ser	His	Gln	Asn	350	355	360
Asn	Pro	His	Gly	Pro	Arg	Glu	Lys	Lys	Ala	Lys	Val	Gly	Ser	Lys	365	370	375
Ala	Gly	Ser	Asn	Lys	Ser	Thr	Ala	Ser	Ser	Lys	Ser	Gly	Asp	Gly	380	385	390
Lys	Asn	Ser	Val	Trp	Ile										395		

- (2) INFORMATION FOR SEQ ID NO:7:
 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 24 bases
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

ATGCCTGACT GGACCGCCTT AGGC 24

- (2) INFORMATION FOR SEQ ID NO:8:
 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 24 bases
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

GATCTCGAGG TCATCAGGCC GAGG 24

- (2) INFORMATION FOR SEQ ID NO:9:
 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 24 bases
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

ATGAGTTGGA GCTTTCTGAC TCGC 24

- (2) INFORMATION FOR SEQ ID NO:10:
 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 24 bases
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

AATCCAGACA GAGTTCTTCC CATC 24

- 42 -

- (2) INFORMATION FOR SEQ ID NO:11:
 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 24 bases
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

ATGGGCGATT GGAGCTTCCT GGGA 24

- (2) INFORMATION FOR SEQ ID NO:12:
 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 24 bases
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

CACTGATAGG TCATCTGACC TTGC 24

- 43 -

WHAT IS CLAIMED IS:

1. A delivery system for delivering a therapeutically effective amount of a predetermined genetic material to an identified cardiac location of a patient's heart, said genetic material being selected for the function of altering the conductivity of cardiac cells to which it is delivered, comprising:
 - a supply of said genetic material;
 - reservoir means for containing said genetic material; and
 - delivery means for delivering said genetic material from said reservoir to said identified cardiac location so as to contact a plurality of cells in the proximity of said cardiac location, thereby changing the conductivity of said cells and improving the cardiac function of said heart.
2. The delivery system of claim 1, wherein said delivery means comprises a catheter with a distal end having an opening at said distal end, said delivery means comprising means for delivering said genetic material from said reservoir through said opening, and further comprising:
 - mapping electrode means positioned at said distal portion for carrying out mapping of the patient's heart so as to identify said cardiac location; and
 - conductor means for connecting said mapping electrode means to the proximal end of said catheter.
3. The delivery system of claim 1, wherein said supply of genetic material comprises a bolus of conduction protein genetic material selected for the function of enhancing cardiac cell conductivity.
4. The delivery system of claim 1, wherein said delivery means comprises a catheter with a distal end

- 44 -

portion, and said reservoir means is located in said distal end portion.

5 5. The delivery system of claim 4, wherein said distal end portion comprises a hollow helical element forming an interior, and said reservoir means comprises said interior with said supply therein.

10 6. The delivery system of claim 1, wherein said delivery means comprises a catheter with a lumen for delivering said genetic material therethrough, said catheter having a distal tip communicating with said lumen for contacting said plurality of cells in the proximity of said cardiac location with said genetic material.

 7. The delivery system of claim 6, wherein said distal tip is a hollow helical needle tip.

15 8. The delivery system of claim 6, wherein said catheter is a transvenous endocardial catheter.

 9. The delivery system of claim 1, wherein said reservoir contains a supply of 0.1-10 ml of said genetic material.

20 10. The delivery system of claim 1, wherein said delivery means comprises a catheter with a distal portion and an end tip, and wherein said reservoir means is contained in said distal portion, and further comprising force means for forcing said genetic material from said reservoir means and out of said end tip.

25

 11. The delivery system of claim 10, wherein said force means comprises a stylet.

- 45 -

12. The delivery system of claim 1, wherein said delivery system comprises a hollow helical screw-in element loaded with a bolus of said genetic material.

13. The delivery system of claim 1, wherein said
5 element comprises ports for egress of said genetic material into said identified cardiac location when said element is screwed into said location, and further comprising soluble plugs in said ports to maintain them normally closed but which dissolve when said element is positioned within said
10 patient's heart.

14. The delivery system of claim 1, wherein said predetermined genetic material is DNA or RNA, and imparts chronic change in conductive properties to said cardiac cells.

15 15. The delivery system of claim 14, wherein said DNA or RNA encodes cardiac gap junction proteins.

16. The delivery system of claim 15, wherein said cardiac gap junction proteins are connexin proteins selected from the group consisting of Cx40, Cx43, and Cx45.

20 17. The delivery system of claim 1, wherein said predetermined genetic material is protein, and imparts acute change in conductive properties to said cardiac cells.

18. The delivery system of claim 17, wherein said protein is cardiac gap junction protein.

25 19. The delivery system of claim 17, wherein said cardiac gap junction proteins are connexin proteins selected from the group consisting of Cx40, Cx43, and Cx45.

20. An implantable delivery system for delivering doses of a therapeutically effective amount of a

- 46 -

predetermined genetic material to an identified cardiac location, comprising:

a supply of genetic material of the class having the property of altering the conductivity of cardiac cells to which it is delivered;

a catheter, said catheter having a distal tip portion for engaging the cells of said cardiac location and delivering thereto said genetic material;

reservoir means for holding said supply of genetic material and providing it to said distal tip portion of said catheter; and

delivery means for delivering a therapeutically effective amount of said genetic material from said reservoir means through said distal tip portion to said cardiac location.

21. The system as described in claim 20, further comprising:

control means for controlling operation of said delivery means to deliver respective said doses.

22. The implantable delivery system of claim 20, wherein said control means comprises initiating means for initiating delivery of said genetic material, said initiating means comprising an external programmer.

23. The implantable delivery system of claim 20, wherein said control means comprises automatic means for automatically initiating delivery of said genetic material.

24. A combined mapping and delivery system for delivering a therapeutically effective amount of a predetermined genetic material to an identified cardiac location of a patient's heart, said genetic material being selected for the function of altering the conductivity of cardiac cells to which it is delivered, comprising:

a supply of said genetic material;

- 47 -


reservoir means for containing said genetic material;

mapping means for identifying cardiac location within a patient's heart; and

5 delivery means within said mapping means for delivering said genetic material from said reservoir to said identified cardiac location so as to contact a plurality of cells in the proximity of said cardiac location, thereby changing the conductivity of said cells and improving the
10 cardiac function of said heart.

25. The combined mapping and delivery system of claim 24, wherein said mapping means comprises a catheter or peelable introducer sheath having two electrodes and said delivery means comprises a catheter having a distal end
15 portion comprising a hollow helical element.

1/6

*FIG. 1*

2/6




FIG. 2




FIG. 3

3/6





FIG. 4



6/6




FIG. 6B

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/06103

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A61K 31/00; A01N 43/04; C07H 21/04
US CL : 604/53; 514/44; 536/23.5

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 604/53; 514/44; 536/23.5

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 94/11506 A1 (ARCH DEVELOPMENT CORPORATION) 26 May 1994, see entire document.	1-25
Y	US 5,328,470 A (NABEL ET AL.) 12 July 1994, see entire document.	1-25
Y	FISHMAN et al. Molecular Characterization and Functional Expression of the Human Cardiac Gap Junction Channel. J. Cell Biol. August 1990, Vol. 111, pages 589-598, see entire document.	1-25
Y	KANTER et al. Molecular Cloning of Two Human Cardiac Gap Junction Proteins, Connexin40 and Connexin45. J. Mol. Cell Cardiol. 1994, Vol. 26, pages 861-868, see entire document.	1-25

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z*	document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means		
P document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search
20 MAY 1997

Date of mailing of the international search report
09 JUN 1997

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231
Facsimile No. (703) 305-3230

Authorized officer
CHRISTOPHER S. F. LOW
Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/06103

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 95/05781 A1 (MEDTRONIC, INC.) 02 March 1995, see entire document.	1-25
Y	WO 93/04724 A1 (MEDTRONIC, INC.) 18 March 1993, see entire document.	1-25
Y	GOURDIE et al. The spatial distribution and relative abundance of gap-junctional connexin40 and connexin43 correlate to functional properties of components of the cardiac atrioventricular conduction system. J. Cell Sci. 1993, Vol. 105, pages 985-991, see entire document.	1-25

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/06103

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

Automated Patent System - USPAT, JPOABS, EPOABS

DIALOG - MEDLINE

Search terms: catheter cardiac stylet gap junction dna protein cx40 cx43 cx45 mapping